OncoMatch/Clinical Trials/NCT06235801
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Is NCT06235801 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Gilteritinib and Momelotinib for myeloid leukemia.
Treatment: Gilteritinib · Momelotinib — To learn the recommended dose of momelotinib that can be given in combination with gilteritinib to participants with AML.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: FLT3 d835
Required: FLT3 d836
Required: FLT3 itd
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: antileukemic therapy
relapsed/refractory FLT3-mutated AML
Cannot have received: investigational antileukemic agents or chemotherapy agents
Exception: unless full recovery from side effects has occurred or participant has rapidly progressive disease judged to be life-threatening by the investigator; prior recent treatment with corticosteroids, hydroxyurea and/or cytarabine (given for cytoreduction) permitted
Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry
Lab requirements
Kidney function
Creatinine clearance ≥ 30 mL/min
Liver function
Total serum bilirubin ≤ 2 x ULN, unless due to Gilbert's syndrome, hemolysis or the underlying leukemia approved by the PI; ALT or AST ≤ 3 x ULN, unless due to the underlying leukemia approved by the PI
Adequate liver and renal function as defined by the following criteria: Total serum bilirubin ≤ 2 x ULN, unless due to Gilbert's syndrome, hemolysis or the underlying leukemia approved by the PI; ALT or AST ≤ 3 x ULN, unless due to the underlying leukemia approved by the PI; Creatinine clearance ≥ 30 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify